SRX Global Q3 net sales up 27% YoY; NAV $3.22/share beats estimate; declares dividend, buyback

SRx Health Solutions, Inc.

2026-Q3 EPS reported -$3.40 revenue$9,638,000

Q3 net sales $3.4M, up 27% YoY; operating loss improved 63% to $3.2M; net loss from continuing ops $4.1M, improved 40% YoY
NAV $62.9M or $3.22/share, above $3.07 preliminary estimate; $36.7M cash, $65.2M current assets, $2.4M liabilities, no debt
Completed EMJX acquisition June 16, 2026; EMJX model max drawdown 10.6% vs 28-58% benchmarks; 4.3% gain in 14-day period vs Bitcoin -10.8%
Declared one-time $0.05/share dividend (~$1.3M); approved 10M share repurchase program; 1-for-60 reverse split effective July 6, 2026
Halo fill rates 93% avg, 98% in June; record Prime Day with 13% NTB growth, CPC $2.51 (8% below pet benchmark)

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.